FORMYCON WKN: A1EWVY ISIN: DE000A1EWVY8 Kürzel: FYB Forum: Aktien Thema: Hauptdiskussion

https://www.google.de/amp/s/seekingalpha.com/amp/news/3542140-j-and-js-stelara-shows-positive-action-in-late-stage-crohns-study

Wieder dabei ☺️

So bin jetzt wieder voll dabei ✌️ nochmal erhöht.

Ziel heute wieder 29! verdammt

value, danke

Mal sehen welchen Zeitplan man jetzt eingehalten bekommt...

This one is a little complex—stick with it, as it could be the first to obtain FDA approval, as early as later this year. Formycon AG, a German manufacturer, gave Bioeq IP AG exclusive global commercialization rights to FYB201, Formycon’s ranibizumab biosimilar. In November 2019, with Formycon’s assent, Bioeq signed an agreement with Coherus Biosciences to commercialize the biosimilar in the US. At the recent JP Morgan investor conference, Coherus President Denny Lanfear disclosed that Bioeq filed for FDA approval in December 2019. Coherus is expecting FDA acceptance of the application shortly, and a fourth quarter 2020 decision. This could set up a product launch, according to Coherus, in 2021. Interestingly, Coherus originally had a different biosimilar ranibizumab in its own pipeline. This agent, CHS-3351, fell by the wayside a couple of years ago. The deal with Bioeq seems to have created a new ranibizumab opportunity for Coherus.

Samsung Bioepis completed its phase 3 trial of SB11 in December 2019 (primary completion date of May 2019). This trial comprised 705 patients with neovascular age-related macular degeneration. SB11 seems poised to be submitted for approval via the 351(k) biosimilar pathway, and Samsung’s deal with Biogen (already a part owner of the joint venture with Samsung Biologics) for commercialization. Therefore, Biogen will take the marketing reins once an FDA decision has been given. If Samsung submits its filing in Q2 2020, a launch could be possible in Q2 2021, assuming a positive decision.

Das meinte ich ja mit größeren Schwankungen durch gering verfügbare Anzahl Aktien und geringe Handelsumsätze. Richtig, Value.

Bezogen auf Xetra

haben nur hektische

Schaut mal mit welcher geringen Menge der Kurs wieder gestiegen ist. Gestern habeb nur gektische Kleinanleger geschmissen. Volumen heute unter 4k Stück. Volumen gestern über 50k Stück.

Genau so! Xetraschluss heute 29 würde mir reichen alles darüber wäre Bonus. läuft

ok. Limit trotz Spread merke ich mir. Ist für Formycon natürlich ideal. Danke für die Informationen. Wiwo mal interessant. Ich bin raus für heute!

https://www.formycon.com/press-release/formycon-informiert-ueber-verlauf-der-kapitalmassnahme/

https://app.handelsblatt.com/unternehmen/industrie/interview-biotech-investor-struengmann-in-deutschland-haetten-wir-null-chancen-gehabt/25300520.html?utm_term=Autofeed&social=tw-hb_hk-li-ne-or-&utm_medium=Social&utm_content=hb_hk&utm_source=Twitter&ticket=ST-2950696-1g06QXncSYcxSMQC7Aqs-ap5#Echobox=1575548907